Randy Robbin

By Randy Robbin

Chief Learning Officer and President, HMP Education

For 2024, this highly anticipated series will be held in new locations, delivering accessible and engaging educational opportunities for healthcare professionals.

Each year, HMP Global produces more than 450 meetings across a range of therapeutic areas, including some of the world’s largest medical education conferences. 

Unique among our meetings is the Great Debates & Updates (GDU) series — held in an interactive, debate-style format that allows participants dedicated time to engage with both faculty experts and other attendees in Q&A, discussion, and exchange on a variety of topics. 

For 2024, this highly anticipated series will be held in new locations, delivering accessible and engaging educational opportunities for healthcare professionals. Expert faculty will offer insightful presentations that challenge the status quo and encourage open dialogue. Sessions will evaluate real-world data, explore new therapeutic regimens, and provide actionable strategies for improved patient care.  

Both in-person and virtual options are available, and registration is free for clinicians. This includes: 

  • Great Debates & Updates in Gastrointestinal Malignancies 
    May 17-18, New York City 
    October 19-20, Dallas 
    Program: GDU in Gastrointestinal Malignancies will focus on the field’s rapidly advancing tailored treatments. Immunotherapy and new combinations for MSI-H patients are gaining traction, while sphincter preservation in rectal cancer remains a priority. We will dive into biomarker research and the potential of ctDNA in expanding and informing treatment decisions. Clinical trials are diversifying with novel drugs, promising a new era of personalized medicine. This dynamic progress emphasizes the field’s relentless pursuit of better outcomes.  
    Chairs: Cathy Eng, MD, FACP, FASCO; Yelena Janjigian, MD 
  • Great Debates & Updates in Hematologic Malignancies 
    April 5-6, New York City 
    May 11 (Myeloma Day), Dallas 
    July 27-28, Los Angeles 
    Program: GDU in Hematologic Malignancies will focus on novel immune therapies such as CAR T cell therapy, antibody-drug conjugates, and bispecific antibodies. Sequencing these therapies and integrating them into treatment algorithms poses complexities and challenges. We will address these agents and their optimal use and mitigation of side effects to better care for patients. 
    Chairs: Jessica K. Altman, MD; John P. Leonard, MD; and Joseph Mikhael, MD, Med, FRCPC, FACP 
  • Great Debates & Updates in Lung Cancers 
    April 27-28, New York City 
    October 5-6, Dallas 
    Program: GDU in Lung Cancers will delve into discussions probing whether ADCs herald the dawn of a new era in therapy as the “New Emperor.” Engage in discourse on the readiness of STK11 and its associated biomarkers, evaluating their potential as guiding beacons in treatment decisions. Additionally, weigh in on the necessity of liquid biopsies in the initial patient workup, exploring their role in unraveling tumor heterogeneity and treatment response.  
    Chairs: Edward B. Garon, MD, MS; and Corey L. Langer, MD, FACP 
  • Great Debates & Updates in Women’s Oncology 
    May 3-4, New York City 
    November 1-2, Nashville 
    Program: GDU in Women’s Oncology explores the multifaceted landscape of treatment choices with antibody-drug conjugates (ADCs) through engaging debates. Dive into topics such as novel agents, HER2 protocols, and immune checkpoint inhibitors, tailored to address diverse disease stages. The discussions will provide insights into navigating the intricacies of therapeutic decisions, offering a comprehensive understanding of treatment approaches across different stages. 
    Chairs: Erika P. Hamilton, MD; and Kathleen N. Moore, MD, MS 

Because these meetings are held in a debate format, they examine crucial decision points that physicians face, while engaging learners more than a traditional lecture would. They spur important dialogue on emerging and controversial topics. A perineal favorite, we get great feedback from GDU participants and faculty. 

HMP Global has long been a leader in high-impact continuing medical education — our GDU series dates back nearly 20 years — and our mission is to provide concise, quality training for oncology professionals. We recruit leading global experts to give our learners a well-rounded view of critical topics. 

We hope you will join us for our best year yet in 2024. For more information or to register, visit hmpglobalevents.com/gdu